Month: May 2023

Advancing clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to Bristol Myers Squibb collaboration AUSTIN, Texas, May 15, 2023 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results and business updates for the first quarter of 2023. Eric Poma, PhD., Chief Executive and Chief Scientific Officer of MTEM, stated, “ETBs represent a novel platform with unique biology for the treatment of patients with disease that has progressed on available therapy. We continue to see an acceptable...

~ Revenue Increased 336% to $17.6 Million Compared to Q1 2022 ~ ~ Key Performance Indicator, Minutes Watched Per Month, Increased to 10.8 Billion from 10.5 Billion in Q1 2022~ ~ Rumble Adds YouTube’s Top US Gaming Streamer, IShowSpeed, and Twitch’s Most-Subscribed Streamer, Kai Cenat ~ ~ Acquires Podcasting and Livestreaming Platform Callin, Founded by David Sacks ~ ~ David Sacks to Join Board of Directors ~ LONGBOAT KEY, Fla., May 15, 2023 (GLOBE NEWSWIRE) — Rumble Inc. (“Rumble”) (NASDAQ: RUM), the popular video-sharing platform, announced today financial results for the fiscal quarter ended March 31, 2023. Q1 2023 HighlightsFirst quarter revenue increased over 336% to $17.6 million, compared to $4.0 million in the first quarter of 2022. Average estimated Minutes Watched Per Month (“MWPM”)...

Wireless Segment Revenue Increase Offset by Telco Segment Revenue Decline as Supply Chain Normalizes CARROLLTON, Texas, May 15, 2023 (GLOBE NEWSWIRE) — ADDvantage Technologies Group, Inc. (NASDAQ: AEY) (“ADDvantage Technologies” or the “Company”) today reported financial results for the three months ended March 31, 2023, the first quarter of 2023. The Company has changed its fiscal year end from September 30 to December 31, and this report reflects that adjustment. “In our wireless segment, weather-related delays impacted results but we continue to win new business and we have barely scratched the surface of the total near-term opportunity,” commented Joe Hart, Chief Executive Officer. “Subsequent to the end of the quarter, Brian Davidson, a strategic sales and marketing executive and thought-leader with nearly 30 years of experience...

Net product sales increased by 94% from Q1 2022New cumulative prescribers up by 17% from Q4 2022Doubled patient enrollment since Q1 2022; 127% increase SOLANA BEACH, Calif., May 15, 2023 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the first quarter ended March 31, 2023, and recent corporate developments. “We are pleased to witness a solid uptick in most categories of our sales growth indicators – net revenue, fills, cumulative prescribers and patient enrollments over the course of the first quarter of 2023. Looking back at our sales metrics in Q4 2022, we returned to normal levels of upward revenue growth and recorded...

Hallmark Financial Services, Inc. Hallmark Financial Services, Inc.DALLAS, May 15, 2023 (GLOBE NEWSWIRE) — Hallmark Financial Services, Inc. (“Hallmark”) (NASDAQ: HALL) today filed its Form 10-Q and announced financial results for the first quarter ended March 31, 2023.  First Quarter    2023     2022  $ in millions:    Net loss from continuing operations $ (39.2 ) $ (11.7 )Net income from discontinued operations $ 0.1   $ 8.5  Net loss $ (39.1 ) $ (3.2 )Operating loss (1) $ (5.0 ) $ (11.7 )     $ per diluted share (2):    Net loss from continuing operations $ (21.59 ) $ (6.43 )Net income from discontinued operations $ 0.06   $ 4.66  Net loss $ (21.53 ) $ (1.77 )Operating loss (1) $ (2.74 ) $ (6.45 )     (1) See “Non-GAAP Financial Measures” below(2) Per share amounts have been restated...

– Topline data for pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected mid-2023 – – Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model – – IND submission for brilaroxazine lipogel in psoriasis expected in 2024 – CUPERTINO, Calif., May 15, 2023 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today reported financial results for the first quarter ended March 31, 2023 and summarized recent business highlights. “We started off 2023 focused on maximizing...

Maroussi, Greece, May 15, 2023 – Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS), (the “Company” or “Pyxis Tankers”), an international pure-play product tanker company, today announced unaudited results for the three months ended March 31, 2023. Summary For the three months ended March 31, 2023, our Revenues, net were $11.6 million. For the same period, our time charter equivalent (“TCE”) revenues were $9.2 million, an increase of approximately $5.4 million or 139% from the comparable quarter in 2022. Our net income attributable to common shareholders for the three months ended March 31, 2023 was $8.7 million, representing an increase of $12.4 million from a net loss of $3.7 million in the comparable period in 2022. For the first quarter of 2023, the net income per share was $0.81 basic and $0.71 diluted compared to a net loss per share of $0.34...

DOYLESTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today reported financial results for the three months ended March 31, 2023 and provided a business update. “We are excited about the strong start for 2023 as we focus on the execution of the pipeline development plan and continue enrollment in our Phase 1/2a dose escalation study of our ATR inhibitor, ATRN-119, in patients with biomarkers related to DDR mutations,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “Our cash position remains strong with a runway to carry us into the third quarter of 2024 and cross meaningful clinical...

Record Revenue Performance of $10.0 Million, Up 48% Net Income Improves By $2.3 Million to $2.9 Million CHANDLER, Ariz., May 15, 2023 (GLOBE NEWSWIRE) — VirTra, Inc. (Nasdaq: VTSI) (“VirTra”), a global provider of judgmental use of force training simulators, firearms training simulators for the law enforcement and military markets, reported results for the first quarter ended March 31, 2023. The financial statements are available on VirTra’s website and here. First Quarter 2023 Financial Summary:Total revenue increased 48% to a record $10.0 million Gross profit increased 88% to $6.9 million, or 69% of total revenue Net income increased by $2.4 million to $2.9 million Adjusted EBITDA increased to $4.0 million Improved strong balance sheet with cash and cash equivalents of $14.3 million at March 31, 2023First Quarter 2023 Financial...